Replies to post #110659 on Amarantus Bioscience Holdings Inc (AMBS)

[GS1]

It is because spinoff doesn't involve R/S. Once diagnostic division is spun it will be new comipany and we will get shares in new company. Another thing Gerald mentioned is uplist from position of strength which means it should be making hundreds of millions in revenue and not 10 million.

Given current position AMBS is in, Except Lympro they don't have any assets that can generate revenues that will allow them to uplist.

AD patients are severly misdiagnosed and hence there are numerous failures in clinical trials. Know what you own..

Lympro is going to knock your socks off..

Stay Tuned...

Happy New Year To All AMBS Board Members

[JPetroInc]

I think Gerald is 1 for 4

1.) Nasdaq Uplist
30% Bonus = $35,437.50

2.) Eltoprazine US IND filed & Approved for LID
30% Bonus = $35,437.50

3.) LymPro Partner Validation of APP & CLIA Certification
25% Bonus = $29,531.24

4.) MANF ODD Apps Filed & Approved for OIA & RP
15% Bonus = $17,718.75


***** GC's Total Bonus = $118,125 *****

that said, personally speaking I believe above milestones would be worth much more to the shareholder community if completed after the 1st then if they were before - hopefully the 'financial advisors' believe so as well and we have them in the chamber currently...